MX387400B - Células de mamífero que expresan antígenos de citomegalovirus. - Google Patents

Células de mamífero que expresan antígenos de citomegalovirus.

Info

Publication number
MX387400B
MX387400B MX2017005661A MX2017005661A MX387400B MX 387400 B MX387400 B MX 387400B MX 2017005661 A MX2017005661 A MX 2017005661A MX 2017005661 A MX2017005661 A MX 2017005661A MX 387400 B MX387400 B MX 387400B
Authority
MX
Mexico
Prior art keywords
cells expressing
mammalian cells
cytomegalovirus antigens
expressing cytomegalovirus
cmv
Prior art date
Application number
MX2017005661A
Other languages
English (en)
Other versions
MX2017005661A (es
Inventor
Anders Lilja
Andrea Carfi
Claudio Ciferri
Holger Laux
Irmgard Hofmann
Yingxia Wen
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2017005661A publication Critical patent/MX2017005661A/es
Publication of MX387400B publication Critical patent/MX387400B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a proteínas de citomegalovirus (CMV) adecuadas para usos en vacunas. En el presente documento se proporcionan células hospederas de mamífero, en particular células CHO, en las que la secuencia o secuencias que codifican las proteínas gH, gL, pUL128, pUL130. pUL131 de CMV (o un fragmento de las mismas que forma complejos) se integran de forma estable en el genoma.
MX2017005661A 2014-10-31 2015-10-29 Células de mamífero que expresan antígenos de citomegalovirus. MX387400B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14191385.5A EP3015475A1 (en) 2014-10-31 2014-10-31 Mammalian cells expressing cytomegalovirus antigens
PCT/IB2015/058349 WO2016067239A1 (en) 2014-10-31 2015-10-29 Mammalian cells expressing cytomegalovirus antigens

Publications (2)

Publication Number Publication Date
MX2017005661A MX2017005661A (es) 2017-06-26
MX387400B true MX387400B (es) 2025-03-18

Family

ID=51844603

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005661A MX387400B (es) 2014-10-31 2015-10-29 Células de mamífero que expresan antígenos de citomegalovirus.

Country Status (19)

Country Link
US (1) US10414802B2 (es)
EP (2) EP3015475A1 (es)
JP (1) JP6688297B2 (es)
CN (1) CN107075486B (es)
AR (1) AR102464A1 (es)
BE (3) BE1023364B1 (es)
BR (1) BR112017008827A2 (es)
CA (1) CA2964859C (es)
CY (1) CY1123405T1 (es)
DK (1) DK3212660T3 (es)
ES (1) ES2799735T3 (es)
HR (1) HRP20200932T1 (es)
HU (1) HUE049356T2 (es)
LT (1) LT3212660T (es)
MX (1) MX387400B (es)
PL (1) PL3212660T3 (es)
PT (1) PT3212660T (es)
SI (1) SI3212660T1 (es)
WO (1) WO2016067239A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2513768B (en) 2012-07-06 2015-04-15 Novartis Ag Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
MX368664B (es) * 2014-04-29 2019-10-10 Novartis Ag Células novedosas de vertebrados y métodos para la expresión recombinante de un polipéptido de interés.
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
CA3041307A1 (en) 2016-10-21 2018-04-26 Giuseppe Ciaramella Human cytomegalovirus vaccine
CN107723276B (zh) * 2017-11-02 2021-08-13 上海交通大学 一种稳定高表达目标产物的细胞株的构建方法和试剂盒
JP7575096B2 (ja) 2018-05-04 2024-10-29 スパイバイオテック・リミテッド ワクチン組成物
KR102609106B1 (ko) * 2018-12-10 2023-12-05 케이엠 바이올로직스 가부시키가이샤 사이토메갈로바이러스의 선천성 감염을 예방 또는 치료하기 위한 백신
CR20220367A (es) * 2020-02-05 2022-08-30 Novartis Ag Célula cho que expresa heterodímeros il-15
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CA3199996A1 (en) * 2020-12-02 2022-06-09 Pirada ALLEN Multicistronic rna vaccines and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
AU635844B2 (en) 1989-11-06 1993-04-01 Cell Genesys, Inc. Production of proteins using homologous recombination
US5589392A (en) 1991-01-14 1996-12-31 Stratagene Nucleic acid construct encoding a nuclear transport peptide operatively linked to an inducible promoter
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
EP3520813B1 (en) * 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
GB2513768B (en) 2012-07-06 2015-04-15 Novartis Ag Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins
WO2014097113A2 (en) 2012-12-18 2014-06-26 Novartis Ag Production of therapeutic proteins in genetically modified mammalian cells
AU2014369177B2 (en) 2013-12-20 2017-04-20 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
EP3604331A1 (en) 2013-12-20 2020-02-05 Novartis AG Novel eukaryotic cells and methods for recombinantly expressing a product of interest
WO2015165480A1 (en) * 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
MX368664B (es) 2014-04-29 2019-10-10 Novartis Ag Células novedosas de vertebrados y métodos para la expresión recombinante de un polipéptido de interés.

Also Published As

Publication number Publication date
CY1123405T1 (el) 2021-12-31
BE1023841B1 (fr) 2017-08-10
BR112017008827A2 (pt) 2018-03-27
EP3212660B1 (en) 2020-03-25
EP3212660A1 (en) 2017-09-06
HRP20200932T1 (hr) 2020-09-18
JP2017534283A (ja) 2017-11-24
CN107075486B (zh) 2021-06-22
BE1023840A1 (fr) 2017-08-09
SI3212660T1 (sl) 2020-07-31
BE1023364B1 (fr) 2017-02-20
US10414802B2 (en) 2019-09-17
CN107075486A (zh) 2017-08-18
CA2964859A1 (en) 2016-05-06
AR102464A1 (es) 2017-03-01
BE1023364A1 (fr) 2017-02-20
WO2016067239A1 (en) 2016-05-06
BE1023841A1 (fr) 2017-08-09
LT3212660T (lt) 2020-07-10
PL3212660T3 (pl) 2020-10-05
PT3212660T (pt) 2020-06-23
MX2017005661A (es) 2017-06-26
ES2799735T3 (es) 2020-12-21
BE1023840B1 (fr) 2017-08-10
DK3212660T3 (da) 2020-06-15
US20170362278A1 (en) 2017-12-21
JP6688297B2 (ja) 2020-04-28
HUE049356T2 (hu) 2020-09-28
EP3015475A1 (en) 2016-05-04
CA2964859C (en) 2023-04-04

Similar Documents

Publication Publication Date Title
MX387400B (es) Células de mamífero que expresan antígenos de citomegalovirus.
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
MX2023001834A (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
PE20181529A1 (es) Vacunas de acido nucleico para el virus varicela-zoster (vzv)
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3389683B8 (en) Virus encoding an anti-tcr-complex antibody or fragment
EA201990959A1 (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
MX395524B (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
MY181175A (en) Therapeutic hpv16 vaccines
MX2018002106A (es) Vacunas terapeuticas contra el hpv18.
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
MX384422B (es) Vector que expresa conjuntamente vacunas y moléculas coestimuladoras
MX2016002166A (es) Anticuerpos.
MY191539A (en) Streptococcal vaccine
MX378905B (es) Pestivirus.
MX2016013584A (es) Parvovirus porcino.
SG10201807572PA (en) Robust antibody purification
CY1120997T1 (el) Πρωτεϊνες συντηξης uti
MY188100A (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
WO2016116905A9 (en) Cmv antigens and uses thereof
BR112015004629A2 (pt) polipeptídeos de clostridium difficile como vacinas
IL265942A (en) A nucleotide sequence expressing an exosome anchor protein for use as a component
MX2017009889A (es) Vacuna a base del citomegalovirus, expresando la glicoproteína del virus del ébola.